[Pyr11]-beta-Amyloid (11-40) – 1 mg

Overview

The [Pyr11]-beta-Amyloid (11-40) peptide is a critical compound in Alzheimer’s disease research, specifically related to the formation of senile plaques. This N-terminally truncated pyroglutamate-modified beta-Amyloid is of particular interest as it includes forms such as Aß(3-40) and Aß(11-40). These forms are significantly more resistant to degradation and are characterized by a higher aggregation propensity compared to their non-modified counterparts. With the growing emphasis on early detection and understanding of Alzheimer’s pathology, this peptide plays a pivotal role in advancing research and potential therapeutic strategies.

Key Features

• Highly relevant for Alzheimer’s disease research
• N-terminally truncated forms contribute to plaque formation
• Greater resistance to degradation enhances study reliability
• Increased toxicity and aggregation propensity observed
• Perfect for use in assays alongside our available PKG substrates

Specifications

FAQ

What is the significance of [Pyr11]-beta-Amyloid?

This peptide is crucial for understanding the mechanisms of Alzheimer’s disease, particularly in the study of senile plaques.

How does [Pyr11]-beta-Amyloid differ from other beta-Amyloid forms?

N-terminal truncation and pyroglutamate modification make it more stable, toxic, and prone to aggregation.

Can [Pyr11]-beta-Amyloid be used in diagnostic assays?

Yes, it is ideal for various assays, especially when combined with our other products like Autocamtide-2 and CREBtide.

Get your [Pyr11]-beta-Amyloid (11-40) now to enhance your research on Alzheimer’s disease. Explore our complete selection of peptides for your study needs.